At Novavax, Inc. (NASDAQ:NVAX), the ratio of insider selling to insider buying over a year is running at 0. Could this be a sign something is cheering insiders? NVAX corporate insiders offloaded no shares on the open market in the last twelve months when buyers snapped up 195,791 shares.
Glenn Gregory M gathered a total of 13.01 thousand shares of Novavax, Inc. (NVAX) at average share price of $0.88. This insider trade in the company took place on 07/31/2018. The total for the purchase was set at $11.45 thousand. After this transaction, the President, R&D account balance stood at 60.22 thousand shares. The stock grew 150 percent since that insider purchase. On 05/14/2018, Erck Stanley C, President and CEO, purchased 100 thousand shares at a price per share of $1.65. This added 165 thousand shares to the insider’s fortune and the stock saw a 33.33 percent rally in value since the news became public. This transaction left 328.28 thousand shares in the President and CEO account.
On 05/14/2018, SVP, CBO and CFO Trizzino John performed a purchase transaction worth $82 thousand. This purchase at $1.64 each has added 50 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded 34.15 percent increase since the transaction was reported. The insider now is left with 138.97 thousand shares remaining in the account. Glenn Gregory M, who performs the President, R&D job, bought 20 thousand shares for $32.8 thousand. The acquisition occurred on 05/14/2018 was priced at $1.64 per share. The share price soared 34.15 percent since the reporting date. Glenn Gregory M now left with a stake of 47.21 thousand NVAX stock worth $103.86 thousand after the insider buying.
The 12-month median price target for Novavax, Inc. (NVAX) assigned by the analysts stands at $3.5, which represents a return potential of 59.09 percent when compared to the closing price of the stock of $2.2 on Friday, January 11. The lowest price target for the stock is $1.5 — slightly more than -31.82 percent from NVAX’s current share price. The stock will probably climb 104.55 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $10-month high price target. This represents a whopping 354.55 percent increase from where shares are trading today.
On momentum oscillators front, ‘RSI’ has touched 55.66 on daily chart, which may remain a cause for concern. If the price breaks below $2.11 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $2.23 mark may result into a pull-back move towards $2.27 level. The stock is currently hovering around the first support level of $2.15. Below this, the next support is placed in the zone of $2.11. Till the time, the NVAX stock trades above this level, bulls have nothing to fear.
Shares of Novavax, Inc. (NVAX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry NVAX operates in has an average P/E of 95.96. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 22.12 on the Price-to-Sales ratio. Compare this with the industry average P/S of 242.95. 0 percent is the gross profit margin for Novavax, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
On 11th of January, Novavax, Inc. (NASDAQ:NVAX) shares ended lower after a volatile session. The shares dropped -0.03 points or -1.35 percent at $2.2 with a heavy trade volume of 7.956 million shares. After opening the session at $2.2, the shares went as high as $2.22 and as low as $2.14, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $854 million and now has 388.09 million shares outstanding. Novavax, Inc. (NVAX) stock has lost -1.35 percent of market value in 21 trading days.
In last reported earnings results, NVAX earned -$0.12 per share, in line with the -$0.12, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $7.74M, worse than the $9.4M analysts expected. Earnings are estimated to increase by 39.3 percent this year, 9.8 percent next year and continue to increase by 0 percent annually for the next 5 years. Investors will get their next glimpse of NVAX’s Q4 earnings on March 04. Analysts are forecasting revenue to suffer decline of -32 percent to $7.08M in the next fiscal quarter, while earnings are seen soaring by nearly -25 percent to -$0.12 per share. History has shown that shares in Novavax, Inc. have gone down on 23 different earnings reaction days and are predicted to add 0.06 percent when the company reports upcoming earnings.
NVAX stock has a trailing 3-year beta of 2.36, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.53 a share in the trailing twelve months. The stock’s value has surged 19.57 percent year to date (YTD) against a rise of 3.77 percent in 12 month’s time. The company’s shares still trade -20 percent away from its 1-year high of $2.75 and 91.3 percent up from 52-week low of $1.15. The average consensus rating on the company is 1.9, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.